Pamplona, Spain – May 11st, 2026 – Palobiofarma S.L., a biopharmaceutical company focused on the discovery and development of innovative treatments for orphan diseases, today announced significant progress in the clinical development of PBF‑999, its novel PDE10 inhibitor for the treatment of Prader‑Willi Syndrome (PWS). The Company has achieved two major milestones: The Phase 2 … Continue reading Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome